Journal List > J Korean Endocr Soc > v.24(4) > 1003515

TOOLS
Lee, Yom, Lim, Kim, Lee, Cho, Lee, Kim, Park, and Lim: A Case of Prolonged Hypoglycemia Post Topiramate Treatment an Anti-convulsant, in a Type 2 Diabetic Patient
Case Report
Journal of Korean Endocrine Society

Journal of Korean Endocrine Society 2009; 24(4): 277-280.

Published online: 31 December 2009

DOI: https://doi.org/10.3803/jkes.2009.24.4.277

A Case of Prolonged Hypoglycemia Post Topiramate Treatment an Anti-convulsant, in a Type 2 Diabetic Patient

Myung Jun Lee, Yoon Shick Yom, Hyun woo Lim, Sung Tae Kim, Yu Mi Lee, Youn Zoo Cho, Kang Woo Lee, Byung Joon Kim, Keun Young Park, Dong Mee Lim

Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Konyang University, Korea.

Received 17 July 2009       Accepted 7 September 2009

Copyright © 2009 Korean Endocrine Society

Abstract

Topiramate is a drug used to treat epilepsy, and is known for its effects including reduced appetite resulting in lower body weight, and the lowering of neutral fat. In addition, topiramate is known to reduce blood sugar levels by increasing insulin sensitivity and by increasing insulin secretion by glucose stimulation. The authors report a case of persistent hypoglycemia, in a patient who had been administrating topiramate, as a treatment for epilepsy following an episode of cerebral infarction.

Keywords: diabetes mellitus, hypoglycemia, topiramate

Figures and Tables

Fig. 1
Pancreatic dynamic CT shows about 2.8 × 2.0 cm-sized, lobulating contoured cystic mass with thin wall, but no enhancing solid portion in pancreatic head (white arrow). There is no associated pancreatic duct dilatation, pancreatic parenchymal swelling, or peripancreatic fluid collection.
jkes-24-277-g001

References

1. Service FJ. Diagnostic approach to adults with hypoglycemic disorders. Endocrinol Metab Clin North Am. 1999. 28:519–532.
2. Choi TJ, Woo JT, Yang IM, Kim SW, Kim JW, Kim YS, Choi YK. Frequency and clinical features of hypoglycemia. J Korean Diabetes Assoc. 1995. 19:72–79.
3. Cho MH, Kim DM, Kim CS, Park JS, Nam JY, Chang JH, Park J, Ahn CW, Cha BS, Lim SK, Kim KR, Lee HC. A case of severe prolonged hypoglycemia caused by combined ramipril and amiloride treatment in a nondiabetic woman. J Korean Diabetes Assoc. 2004. 28:554–557.
4. Hong JH, Lim EJ, Lee JM, Chang SA. A case of insulin autoimmune syndrome that developed after topiramate anti-obesity medication. Korean J Med. 2008. 75:866–869.
5. Wilkes JJ, Nelson E, Osborne M, Demarest KT, Olefsky JM. Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab. 2005. 288:E617–E624.
6. Astrup A, Toubro S. Topiramate: a new potential pharmacological treatment for obesity. Obes Res. 2004. 12:S167–S173.
7. Glauser TA. Topiramate. Epilepsia. 1999. 40:S71–S80.
8. Liang Y, Chen X, Osborne M, DeCarlo SO, Jetton TL, Demarest K. Topiramate ameliorates hyperglycaemia and improves glucose-stimulated insulin release in ZDF rats and db/db mice. Diabetes Obes Metab. 2005. 7:360–369.
9. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation. 2000. 101:2047–2052.
10. Lee KW. Hypoglycemia. J Korean Soc Endocrinol. 1993. 8:231–240.
11. de Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, Kwekkeboom DJ, Oberg K, Eriksson B, Wiedenmann B, Rindi G, O'Toole D, Ferone D. Frascati Consensus Conference; European Neuroendocrine Tumor Society: Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006. 84:183–188.
12. Roy Chengappa KN, Levine J, Rathore D, Parepally H, Atzert R. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry. 2001. 16:186–190.
13. Stenlof K, Rossner S, Vercruysse F, Kumar A, Fitchet M, Sjostrom L. OBDM-003 Study Group: Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab. 2007. 9:360–368.
14. Eliasson B, Gudbjornsdottir S, Cederholm J, Liang Y, Vercruysse F, Smith U. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes (Lond). 2007. 31:1140–1147.
TOOLS
Similar articles